Transaction #9502 · Form 4 · 0001213900-25-112277

Vyome Holdings, Inc · Stock award · Common Stock

Vyome Holdings, Inc · Transacted August 15, 2025 · Filed November 18, 2025

Original SEC filing ↗

What does this filing report?

An SEC Form 4 filing for Vyome Holdings, Inc records a stock award involving Common Stock on August 15, 2025. The reported quantity was 454,456. The filing date is November 18, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Transaction details

Company CIK
0001427570
Security type
Non-derivative
Acquisition type
Stock award · Code A
Quantity acquired
454,456
Reported price
Not reported · See footnotes
Reference value
Not reported
Currency
Currency not specified
Ownership
Indirect
Holdings after transaction
454,456
Ownership description
See footnote
SEC acceptance time
Nov 18, 2025, 6:45 PM EST
10b5-1 indication
Not indicated

Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.

Reporting owners

These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.

Company listings

HIND · Nasdaq · linked security

The linked listing is identified separately from other current company listings.

Filing footnotes & remarks

F1
Under the terms of the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Raider Lifesciences Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome Therapeutics"), on August 15, 2025, Merger Sub merged with and into Vyome Therapeutics, with Vyome Therapeutics surviving the merger as a subsidiary of the Issuer (the "Merger"). Upon the closing of the Merger, each share of common and preferred stock of Vyome Therapeutics, was converted into the right to receive 1 share of the Issuer's common stock for every 5,000 shares of Vyome Therapeutics. As a result of the Merger, the Issuer was renamed "Vyome Holdings, Inc." and Vyome Therapeutics continued under its name as Vyome Therapeutics, Inc. The reporting person received 454,456 shares of the Issuer's common stock in exchange for 2,272,280,000 shares of common stock of Vyome Therapeutics pursuant to the Merger Agreement.
F2
Includes indirect beneficial ownership of 454,456 shares of common stock held by Iron Pillar Fund I Ltd. Mohanjit Jolly is a general partner of Iron Pillar Fund I Ltd. and an advisor to and representative of Iron Pillar India Fund I for investments in the Issuer.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.

This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.